

OPTIONAL COURSE 5 CREDITS

PROF. JOSEPH BORG

THE AUTHORIZATION OF MEDICINAL PRODUCTS IN THE EU.

1. Part 1 EU Directives and Regulations on Medicinal products
General Aspects of the EU legislation – covering Named patient basis/compassionate use/
public health authorisations, industrial manufacturing, national marketing authorisations,
decentralised and mutual recognition, referral procedures, arbitration at the European
Medicines Agency, CHMP.
2. Part 2 EU Directives and Regulations on Medicinal products
Pharmacovigilance regulations and obligations
3. Part 3 EU Directives and Regulations on Medicinal products
Risk Management Plans and Advertising of Medicinal products issues and case examples
4. The EU regulatory Framework on Biosimilars
General aspects on Biosimilars/Quality-clinical programs and regulatory updates.
5. How to assess a medicinal product including an OTC.
6. General aspects on what assessors do when evaluating risk/benefit of medicines and OTC
7. Part 1 the well established use licensing of medicinal products
Extrapolation of literature data to support a marketing authorisation
8. Does the Regulator face ethical issues
Updates on the clinical trial regulation and a case example of ECMO.
9. Part I pre-clinical data required to support a medicine's safety - Ion channel of excitable
membranes
General aspects of receptors and electrophysiology
10. Part 2 – pre-clinical data required to support a medicine's safety - Applying basic concepts to
understand clinical relevance
11. Part 3 - pre-clinical data required to support a medicine's safety – ICHS7A & ICHS7B
explained
General discussion on how industry assesses cardiac safety of medicines in development.
12. Part 4 - pre-clinical data required to support a medicine's safety – juvenile toxicology studies
13. Part 5 - pre-clinical data required to support a medicine's safety – Non-Clinical Investigation
of the Dependence Potential of Medicinal Products

14. Part 6 - data required to support a medicine's safety – Biotech products

15. Part 7- data required to support a medicine's safety – anticancer/DSMBs/Extrapolation of Animal data.

16. Licensing of Generics - Understanding Bioequivalence studies and the analytical method part 1

17. Licensing of Generics - Understanding Bioequivalence studies and the analytical method part 2